ImmunoGen Inc Stock Research

Market Summary

USD13.92+0.28

Delayedas of 01 Jun 2023, 12:04 pm

2.05%

IMGN Alerts

Big jump in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

IMGN Stock Price

IMGN RSI Chart

IMGN Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-12.86

Price/Sales (Trailing)

25.57

EV/EBITDA

-13.1

Price/Free Cashflow

-11.71

IMGN Price/Sales (Trailing)

IMGN Profitability

Return on Equity

-143.06%

Return on Assets

-63.89%

Free Cashflow Yield

-8.54%

IMGN Fundamentals

IMGN Revenue

Revenue (TTM)

120.6M

Revenue Y/Y

30.97%

Revenue Q/Q

21.14%

IMGN Earnings

Earnings (TTM)

-239.8M

Earnings Y/Y

-69.87%

Earnings Q/Q

30.49%

Price Action

52 Week Range

3.1014.91

(Low)(High)

Last 7 days

-0.2%

Last 30 days

147.6%

Last 90 days

206.5%

Trailing 12 Months

272.7%

IMGN Financial Health

Current Ratio

2.5

IMGN Investor Care

Buy Backs (1Y)

10.74%

Diluted EPS (TTM)

-0.88

Peers (Alternatives to ImmunoGen)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	301.1B	1.6B	-15.02%	61.00%	-157.04	193.34	77.54%	1.62%
ABBV	285.4B	56.7B	-10.25%	-4.55%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-8.82%	10.65%	20.2	7.2	-25.07%	-47.28%
VRTX	83.3B	9.2B	-6.21%	20.44%	25.56	9.05	15.86%	32.99%
ALNY	23.0B	1.0B	-8.35%	47.07%	-21.58	22.16	22.88%	-19.27%
SRPT	11.5B	975.7M	-1.21%	69.73%	-10.32	11.8	27.41%	-212.78%
UTHR	9.8B	2.0B	-9.64%	-8.94%	13.47	4.94	12.05%	52.86%
MID-CAP
MDGL	5.1B	-	-10.01%	319.36%	-16.17	2.5K	-	-27.52%
RARE	3.5B	363.3M	12.11%	5.25%	-4.9	9.54	3.39%	-55.81%
BPMC	3.4B	204.6M	9.75%	2.76%	-5.88	16.69	-7.52%	10.65%
MRTX	2.2B	18.9M	-19.01%	-5.11%	-2.93	114.36	-	-16.17%
SMALL-CAP
CYTK	3.6B	-	-0.21%	-5.54%	-8.3	37.79	34.30%	-67.22%
CPRX	1.2B	256.5M	-31.82%	60.42%	12.31	4.77	66.85%	120.61%
MGNX	288.8M	165.3M	-36.98%	34.58%	-3.16	1.75	130.70%	57.97%
CRBP	39.9M	-	11.67%	3021.29%	-0.79	19.11	-	-29.84%

Financials for ImmunoGen

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	10.8%	120,573,000	108,782,000	95,607,000	89,442,000	92,228,000
Operating Expenses	9.5%	361,007,000	329,675,000	291,495,000	242,135,000	211,237,000
S&GA Expenses	20.1%	139,497,000	116,129,000	87,642,000	64,316,000	50,251,000
R&D Expenses	3.4%	220,708,000	213,370,000	203,853,000	177,819,000	160,986,000
EBITDA	-0.1%	-137,401,000	-137,317,000	-	-	-
EBITDA Margin	-3.2%	-1.54	-1.49	-	-	-
Earnings Before Taxes	-	-221,711,000	-	-	-	-
EBT Margin	-3.1%	-1.56	-1.51	-	-	-
Net Income	-7.6%	-239,798,000	-222,929,000	-201,093,000	-160,677,000	-129,397,000
Net Income Margin	2.6%	-2.05	-2.10	-1.80	-1.40	-
Free Cahsflow	-6.5%	-231,166,000	-216,962,000	-187,317,000	-167,045,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-17.4%	288	349	359	422	482
Current Assets	-19.8%	244	304	330	394	457
Cash Equivalents	-26.9%	201	275	310	374	438
Inventory	Infinity%	1.00	-	-	-	-
Net PPE	-7.1%	4.00	4.00	4.00	4.00	4.00
Liabilities	-13.8%	166	193	181	172	175
Current Liabilities	-16.6%	102	122	104	87.00	84.00
Shareholder's Equity	-21.8%	122	156	178	250	306
Retained Earnings	-0.3%	-1,700	-1,694	-1,600	-1,557	-1,500
Additional Paid-In Capital	0.4%	1,855	1,848	1,811	1,805	1,800
Shares Outstanding	0.0%	226	226	221	221	253

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-14.1%	-262,119	-229,802	-215,477	-186,309	-166,197
Share Based Compensation	10.4%	28,275	25,615	21,295	19,290	18,059
Cashflow From Investing	7.2%	-1,266	-1,364	-1,485	-1,008	-848
Cashflow From Financing	-2.1%	26,973	27,554	280,712	321,653	321,586

Risks for IMGN

What is the probability of a big loss on IMGN?

100%

Probability that ImmunoGen stock will be more than 20% underwater in next one year

98.1%

Probability that ImmunoGen stock will be more than 30% underwater in next one year.

82.3%

Probability that ImmunoGen stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IMGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ImmunoGen was unfortunately bought at previous high price.

Drawdowns

Returns for IMGN

Cumulative Returns on IMGN

-2.9%

10-Year Cumulative Returns

13.1%

7-Year Cumulative Returns

3.4%

5-Year Cumulative Returns

42.8%

3-Year Cumulative Returns

What are the long-term rolling returns for IMGN?

FIve years rolling returns for ImmunoGen.

Annualized Returns

Which funds bought or sold IMGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-11.57	-71,772	155,808	-%
2023-05-22	PUTNAM INVESTMENTS LLC	added	2.66	-1,141,280	4,420,430	0.01%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-0.31	-325,431	1,101,570	-%
2023-05-18	JPMORGAN CHASE & CO	added	347	2,646,120	3,720,120	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	10.56	-156,000	928,000	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	sold off	-100	-76,958	-	-%
2023-05-16	Apollon Wealth Management, LLC	new	-	192,000	192,000	0.01%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	102	919,658	2,529,850	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-3,000	-	-%
2023-05-16	JANE STREET GROUP, LLC	reduced	-75.86	-277,816	63,863	-%

Latest Funds Activity

Are funds buying IMGN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own IMGN

No. of Funds

ImmunoGen News

Schedule 13G FIlings of ImmunoGen

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	redmile group, llc	8.6%	19,896,453	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	22,075,158	SC 13G/A
Feb 10, 2023	flynn james e	2.88%	6,358,314	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	6.51%	14,378,435	SC 13G/A
Feb 08, 2023	state street corp	7.93%	17,508,113	SC 13G/A
Feb 06, 2023	wellington management group llp	4.18%	9,226,708	SC 13G/A
Feb 03, 2023	blackrock inc.	8.2%	18,016,002	SC 13G/A
Dec 27, 2022	adage capital partners gp, l.l.c.	5.04%	11,119,000	SC 13G
May 19, 2022	flynn james e	6.70%	14,779,590	SC 13G

IMGN Fair Value

Show Fair-Value

Recent SEC filings of ImmunoGen

View All Filings

Date Filed	Form Type	Document
May 05, 2023	144	Notice of Insider Sale Intent
May 05, 2023	424B5	Prospectus Filed
May 05, 2023	8-K	Current Report
May 03, 2023	424B5	Prospectus Filed
May 03, 2023	8-K	Current Report
May 02, 2023	3	Insider Trading
May 02, 2023	4	Insider Trading
May 02, 2023	8-K	Current Report
Apr 28, 2023	S-8	Employee Benefits Plan
Apr 28, 2023	10-Q	Quarterly Report

Latest Insider Trading transactions for IMGN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-31	Thackray Helen M.	acquired	7,499	3.84	1,953	-
2023-03-31	Arbuckle Stuart A	acquired	13,121	3.84	3,417	-
2023-03-31	Goldberg Mark Alan	acquired	16,873	3.84	4,394	-
2022-12-30	Wingrove Theresa	acquired	4,433	3.92	1,131	svp of regulatory affairs
2022-12-30	Lentini Renee	acquired	5,295	3.92	1,351	v.p.-fin., prin. acctg. off.
2022-12-30	Berkenblit Anna	acquired	1,709	3.92	436	svp & chief medical officer
2022-11-15	Harrington-Smith Kristen	acquired	-	-	25,000	svp & chief commercial officer
2022-06-30	Coen Stacy Ann	acquired	12,783	3.825	3,342	svp & chief business officer
2022-06-30	Berkenblit Anna	acquired	11,754	3.825	3,073	svp & chief medical officer
2022-06-30	Lentini Renee	acquired	9,596	3.825	2,509	v.p.-fin., prin. acctg. off.

About ImmunoGen

Mark J. Enyedy

www.immunogen.com

110

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

IMGN Income Statement

2023-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 49,869	$ 38,078
Cost and operating expenses:
Cost of sales	626
Research and development	51,620	44,282
Selling, general and administrative	40,016	16,648
Total cost and operating expenses	92,262	60,930
Loss from operations	(42,393)	(22,852)
Investment income, net	2,169	54
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(853)	(1,249)
Other (expense) income, net	63	(98)
Net loss	$ (41,014)	$ (24,145)
Basic net loss per common share	$ (0.16)	$ (0.10)
Diluted net loss per common share			$ (0.34)	$ (0.32)
Basic weighted average common shares outstanding (in shares)	258,848	253,263
Diluted weighted average common shares outstanding (in shares)			253,263	199,365
Total comprehensive loss	$ (41,014)	$ (24,145)
License and milestone fees
Revenues:
Total revenues	15,031	30,892
Non-cash royalty revenue related to the sale of future royalties
Revenues:
Total revenues	4,839	6,428
Research and development support
Revenues:
Total revenues	455	$ 758
Product revenue, net
Revenues:
Total revenues	$ 29,544

IMGN Balance Sheet

2023-03-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 201,249,000	$ 275,138,000
Accounts receivable	27,342,000	12,596,000
Unbilled receivable	1,249,000	1,531,000
Non-cash royalty receivable	2,455,000	3,851,000
Inventory	614,000
Prepaid and other current assets	10,955,000	11,005,000
Total current assets	243,864,000	304,121,000
Property and equipment, net of accumulated depreciation	4,067,000	4,377,000
Operating lease right-of-use assets	9,627,000	10,231,000
Long-term inventory	16,291,000	16,196,000
Other assets	14,496,000	14,011,000
Total assets	288,345,000	348,936,000
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable	32,260,000	45,353,000
Accrued compensation	11,780,000	11,111,000
Other accrued liabilities	30,918,000	38,783,000
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $150 and $162, respectively	9,014,000	8,659,000
Current portion of operating lease liability	4,213,000	4,096,000
Current portion of deferred revenue	13,444,000	13,856,000
Total current liabilities	101,629,000	121,858,000
Deferred revenue, net of current portion	34,055,000	36,355,000
Operating lease liability, net of current portion	10,049,000	11,148,000
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $172 and $205, respectively	20,394,000	23,449,000
Other long-term liabilities	300,000	300,000
Total liabilities	166,427,000	193,110,000
Commitments and contingencies (Note L)
Shareholders' equity:
Preferred stock, $.01 par value; authorized 5,000 shares; no shares issued and outstanding as of each of March 31, 2023 and December 31, 2022, respectively
Common stock, $.01 par value; authorized 600,000 shares; 226,070 and 220,046 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	2,261,000	2,260,000
Additional paid-in capital	1,854,743,000	1,847,638,000
Accumulated deficit	(1,735,086,000)	(1,694,072,000)
Total shareholders' equity	121,918,000	155,826,000
Total liabilities and shareholders' equity	$ 288,345,000	$ 348,936,000